1. ALLA AKTIER
  2. NYHETER
  3. 2CUREX

2cureX

Nyheter 2cureX Nyheter alla bolag
Hej Visste du att du med vår premiumtjänst får fullständig historik i alla grafer, pressmeddelanden och andra notiser för dina favoritbolag direkt som DM i Discord samt en del andra godsaker? Du slipper dessutom störande annonser på sajten. Testa gratis i 14 dagar!

We invite you to join the 2cureX Q1 Report webcast and Q&A session at 15:00 on 24 May, 2022

2cureX will publish its Q1 2022 interim report on Tuesday, 24 May 2022 at 12:00 CET. On the same day, we will be holding a webcast and interactive Question and Answer session at 15:00 CET.

First Ole Thastrup (CSO), Fernando Andreu (CEO) and Kenneth Graabek Johansen (CFO) will present the company update for the rest of 2022. Next, there will be an opportunity for you to ask any questions you have about the results and the forecast.

Access to the event is as follows: LIVE access on Tuesday 24 May 2022 at 15:00 CET https://www.2curex.com/live-event-24-05-2022/

For more information about 2cureX:

Fernando Andreu, Chief Executive Officer
E-mail: fa@2curex.com
Telephone: +45 2279 5399
www.2curex.com

About 2cureX

2cureX is a leader in cancer drug sensitivity testing and has developed the IndiTreat® (Individual Treatment) family of tests. Starting from a sample of the patient’s tumor, IndiTreat® creates thousands of 3D replicas (tumoroids) and predicts the tumor response to the different available drugs, providing the physician with valuable information to make the treatment decisions.

The portfolio of IndiTreat® tests is aimed at optimizing treatment decisions in patients with metastatic colorectal cancer (IndiTreat® mCRC Start for first line of therapy, IndiTreat® mCRC Extend and IndiTreat® mCRC Explore for third line). Additional tests are under development to cover other stages of colorectal cancer as well as other gastrointestinal cancers.

According to several reports, the total yearly expenditure in cancer-related In Vitro Diagnostic (IVD) tests exceeds 17.5Bn USD worldwide, from which 2.5 Bn USD are tests directly related to therapy decision making, with a CAGR of 12.7%. Despite this, only one third of all cancer treatments are supported by one of these tests. IndiTreat® aims at filling this gap and making Precision Oncology available to all cancer patients.

The company is listed on Nasdaq First North Growth Market in Stockholm (symbol: "2CUREX"). For more information about 2cureX visit www.2cureX.com
 
Certified Adviser: Redeye AB, +46 8 121 576 90, certifiedadviser@redeye.se

Attachments

Invitation with graphics
We invite you to join the 2cureX Q1 Report webcast and Q&A session at 15:00 on 24 May, 2022

Datum 2022-05-20, kl 13:45
Källa MFN
Bifogade filer
Invitation with graphics
We invite you to join the 2cureX Q1 Report webcast and Q&A session at 15:00 on 24 May, 2022